Funding led by 4point0 Health Ventures to accelerate innovation in wound care and minimally invasive aesthetics.
MedVital, a pioneering MedTech startup focused on advanced technologies for hard-to-heal wounds and minimally invasive aesthetics, has raised 8.4 crore in pre-seed funding. The round was led by Nihar Parikh’s 4point0 Health Ventures, with participation from prominent operator-investors, including founders of Tata 1mg, NephroPlus, SafeExpress, Eye Q Hospital, Hexa Health, and AstroTalk.
India’s healthcare system is at a critical juncture, with a growing burden of hard-to-heal wounds driven by aging, diabetes, obesity, and trauma, alongside rising demand for minimally invasive aesthetic solutions. MedVital aims to bridge this gap by creating India’s first integrated platform for complex wound care and minimally invasive aesthetics. Their flagship product, NoWound™, is a state-of-the-art Negative Pressure Wound Therapy (NPWT) device designed for precision-controlled healing in hospitals, clinics, and home-care settings.
“We are building a full-stack platform that integrates clinically proven devices, intelligent monitoring, and next-generation biomaterials to transform how complex wounds are treated and how patients recover.” – Dr. Varun Gupta, Co-Founder and CEO of MedVital
“MedVital was founded on the belief that skin repair and restoration deserve the same level of innovation and investment as any other critical area of medicine,” said Dr. Varun Gupta, Co-Founder and CEO of MedVital. “This funding allows us to accelerate our mission, strengthen our infrastructure, and scale with purpose.”
The fresh capital will be used to expand MedVital’s product portfolio, strengthen its supply chain, and broaden its distribution network to cover tertiary care hospitals, rural clinics, and home-care settings. Tarun Bansal, Co-Founder and COO, emphasized their vision to make India a global hub for cutting-edge wound care and skin restoration solutions.
Nihar Parikh, Founder of 4point0 Health Ventures, highlighted MedVital’s strategic approach to hard-to-heal wound management and minimally invasive treatments, positioning them uniquely in the healthcare landscape.
Building on this momentum, MedVital plans to launch liquid chitosan-based dressings for hard-to-heal wounds and expand into dermal and hair regeneration solutions, unlocking new clinical pathways in both therapeutic and aesthetic care. With a robust roadmap and growing clinical footprint, MedVital is poised to become a leader in regenerative medicine, backed by science, built in India, and made for the world.
